osm-3 Antibody
Description
OSM and Its Receptors: Biological Context
OSM binds to two receptor complexes:
-
Type I: gp130 + leukemia inhibitory factor receptor (LIFR)
-
Type II: gp130 + OSMRβ
These interactions activate signaling pathways such as JAK/STAT, MAPK, and PI3K/AKT, driving pro-inflammatory cytokine production, fibrosis, and tumor growth . OSM is implicated in RA, SSc, and cancers, where it promotes synovial fibroblast invasion, fibrotic tissue deposition, and metastasis .
Anti-OSM Antibodies
Note: While anti-OSM antibodies like GSK2330811 neutralize OSM directly, their clinical utility is limited by on-target toxicities (e.g., hematologic effects) .
Anti-OSMRβ Antibodies
Key Insight: Anti-OSMR antibodies show broader therapeutic potential by targeting the receptor rather than the cytokine, potentially avoiding systemic OSM suppression .
OSMR-STAT3 Axis in Cancer
-
Ovarian Cancer: OSMR overexpression correlates with metastasis and cisplatin resistance. Anti-OSMR antibodies (e.g., B14/B21) block STAT3 activation, reducing tumor growth and peritoneal dissemination .
-
Glioblastoma: OSMRβ knockdown suppresses STAT3-driven mesenchymal transition and tumor growth .
Fibrotic Diseases
In SSc, OSMRβ expression in fibroblasts and endothelial cells drives collagen deposition and vascular remodeling. Anti-OSM/OSMR strategies aim to disrupt this axis but face challenges in clinical translation .
Clinical Trials and Challenges
-
Bispecific Antibodies: Combining anti-OSMR with anti-PD-1/PD-L1 to enhance immunotherapy in cancers.
-
Biomarker-Driven Trials: Stratifying patients by OSMRβ expression levels to optimize therapeutic response .
Comparative Analysis of OSM-Targeting Strategies
| Strategy | Advantages | Limitations |
|---|---|---|
| Anti-OSM (e.g., GSK2330811) | Direct neutralization of cytokine | Systemic OSM suppression; hematologic toxicity |
| Anti-OSMR (e.g., B14/B21) | Tissue-specific targeting; preserves anti-inflammatory OSM roles | Requires OSMRβ expression in target tissues |
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- OSM-3 mutations result in both NPHP-4 dependent and independent phenotypes. PMID: 26863025
- Research findings indicate that kinesin-II and OSM-3 facilitate ciliary import and long-range transport. PMID: 26523365
- Dauer pheromone and gpa-3 signaling influence the coordination of intraflagellar transport of kinesin-II and OSM-3. PMID: 20501698
- OSM-3 functions as an accessory intraflagellar transport (IFT) kinesin motor; subtle modifications in its deployment or actions can contribute to variations in cilia morphology, cilia function, and sensory perception. PMID: 16492809
- Wild-type organisms exhibit the expression of an L1 (first larval stage) surface epitope in later larval stages when cultivated in spent culture medium. This expression is absent in chemotaxis-defective osm-3 mutants. PMID: 16879619
- Using a single-molecule fluorescence assay, researchers demonstrated that bacterially expressed OSM-3 in solution lacks processive movement and displays low microtubule-stimulated adenosine triphosphatase (ATPase) activity. PMID: 17000874
